V gel
V gel Price range: $ 55,00 through $ 225,00
Back to products
Valtrex
Valtrex Price range: $ 103,00 through $ 506,00

Valif

Price range: $ 50,00 through $ 500,00

Valif is a potent medication specifically formulated to help men effectively manage the symptoms of erectile dysfunction. Its primary active ingredient, Vardenafil, works by enhancing blood flow to key areas to ensure a firm and sustained physical response. This treatment provides a reliable way to regain confidence and improve performance during intimate moments. Known for its rapid onset, Valif allows for greater spontaneity and provides consistent support for an extended period. It is a trusted choice for those seeking an efficient and high-quality solution to enhance their overall physical well-being.

Active substance: Vardenafil
SKU: Valif Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Valif belongs to a class of pharmacological agents known as phosphodiesterase type 5 (PDE5) inhibitors, containing vardenafil as its active pharmaceutical ingredient. It is primarily indicated for the management of erectile dysfunction in adult males, functioning through the target-specific modulation of vascular smooth muscle tone and local hemodynamics.

Within the United States, oral formulations containing vardenafil are categorized as prescription-only (Rx) medications. Federal law restricts these agents to use by or on the lawful order of a licensed healthcare practitioner, requiring an individualized clinical evaluation and valid prescription prior to dispensation in accordance with federal and state regulations.

Parameter Clinical Details
Active Ingredient (INN) Vardenafil
Therapeutic Class Phosphodiesterase Type 5 (PDE5) Inhibitor
Dosage Form Oral Tablet
Route of Administration Oral
Prescription Status Prescription Only (Rx)
Primary Indication Erectile Dysfunction
Onset of Action Typically 30 to 60 minutes post-administration
Storage Conditions Controlled room temperature (68°F to 77°F / 20°C to 25°C)

Clinical Profile and Pharmacological Properties

Mechanism of Action

Vardenafil operates via the potent and selective competitive inhibition of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5. Under normal physiological conditions, sexual stimulation prompts the local release of nitric oxide (NO) from non-adrenergic, non-cholinergic neurons and vascular endothelial cells within the corpus cavernosum of the penis. Nitric oxide subsequently diffuses into smooth muscle cells, activating the intracellular enzyme guanylate cyclase, which converts guanosine triphosphate (GTP) into cGMP.

Elevated levels of intracellular cGMP trigger a signaling cascade that reduces cytosolic calcium concentrations, leading to smooth muscle relaxation, arterial vasodilation, and increased blood flow into the cavernous tissue. PDE5 is the primary enzyme responsible for the hydrolytic degradation of cGMP in the penis. By selectively inhibiting PDE5, vardenafil preserves intracellular cGMP concentrations, thereby potentiating the physiological erectile response to sexual arousal. Vardenafil exhibits no direct relaxant effect on isolated human corpus cavernosum in the absence of upstream nitric oxide release.

Indications and Regulatory Scope

Valif is indicated for the medical treatment of erectile dysfunction (ED) in adult males. Erectile dysfunction is clinically defined as the persistent or recurrent inability to attain or maintain a penile erection adequate for satisfactory sexual activity. The therapeutic efficacy of vardenafil relies upon functional neurovascular pathways; it does not act as an aphrodisiac, nor does it alter hormonal baselines.

Any application of vardenafil outside of confirmed erectile dysfunction–such as secondary vascular applications or off-label use for Raynaud’s phenomenon–is classified as off-label prescribing under FDA regulatory frameworks. Off-label use must be explicitly directed, evaluated, and monitored by a qualified healthcare professional who has thoroughly assessed the relative clinical risks and benefits.

Pharmacokinetics and Metabolism

Following oral administration, vardenafil is rapidly absorbed across the gastrointestinal mucosa. Peak plasma concentrations (Cmax) are typically achieved within 30 to 120 minutes (with a median Tmax of 60 minutes) when taken under fasting conditions. The absolute oral bioavailability of vardenafil is estimated at approximately 15%, primarily due to significant first-pass hepatic metabolism.

Vardenafil and its primary circulating metabolites display extensive binding to plasma proteins (approximately 95%), a process that is fully reversible and independent of total drug concentration. The volume of distribution at steady state averages roughly 208 liters, indicating widespread tissue distribution.

Metabolism of vardenafil is predominantly localized to the liver via the cytochrome P450 (CYP) 3A4 enzyme system, with minor contributions from CYP3A5 and CYP2C isoforms. The major circulating metabolite, designated as M1 (desethyl vardenafil), results from de-ethylation of the piperazine moiety. M1 accounts for approximately 7% of total systemic drug exposure and demonstrates a PDE5 inhibitory potency equivalent to roughly 28% of the parent drug. The mean elimination half-life (t1/2) of vardenafil ranges between 4 and 5 hours. Excretion occurs primarily via the hepatic route into feces (roughly 2 to 69%), with renal excretion playing a secondary role (approximately 2 to 13%).

Safety Parameters, Risk Management, and Administration

Dosage and Administration Guidelines

Dosing of vardenafil must be individually tailored by a licensed prescriber, taking into account patient efficacy, tolerability, and underlying baseline medical history. For most adult patients, the standard recommended initial dose is determined by the provider and administered approximately 60 minutes prior to anticipated sexual activity. The maximum recommended dosing frequency is once per 24-hour period.

Specific patient populations require dosage modifications. Initial dosing reductions are indicated for geriatric patients aged 65 years and older, as well as individuals with moderate hepatic impairment (Child-Pugh Class B) due to decreased hepatic clearance. Patients with severe renal impairment or end-stage renal disease should also be dosed with extreme caution under specialized guidance. Tablets must be swallowed whole with a glass of water.

Drug Interactions and Compatibility

Vardenafil exhibits profound pharmacodynamic and pharmacokinetic interactions with several co-administered therapeutic agents. The concurrent administration of vardenafil with organic nitrates (e.g., nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) or nitric oxide donors (such as amyl nitrite) in any form is strictly contraindicated. Co-administration can induce severe, unpredictable, and potentially fatal systemic hypotension due to synergistic amplification of cGMP-mediated vascular smooth muscle relaxation.

Concomitant administration with soluble guanylate cyclase (sGC) stimulators, such as riociguat, is likewise contraindicated due to heightened risks of systemic hypotension. Caution is required when combining vardenafil with alpha-adrenergic receptor antagonists (alpha-blockers) prescribed for hypertension or benign prostatic hyperplasia. Patients should be hemodynamically stable on their alpha-blocker regimen prior to initiating PDE5 inhibitor therapy to reduce the risk of symptomatic orthostatic hypotension or syncope.

Pharmacokinetic interactions occur with agents that modulate hepatic microsomal enzymes. Strong CYP3A4 inhibitors (including ketoconazole, itraconazole, ritonavir, and indinavir) significantly elevate vardenafil systemic exposure (AUC) and peak plasma levels, necessitating strict dose caps or complete avoidance. Conversely, potent CYP3A4 inducers (such as rifampin, carbamazepine, or St. John’s wort) may markedly decrease vardenafil plasma concentrations, compromising therapeutic efficacy.

Adverse Reactions and Tolerability Profile

Adverse events reported with vardenafil therapy are generally lightweight to moderate, self-limiting, and primarily attributable to systemic peripheral vasodilation. The most frequently reported adverse effects in clinical evaluations include:

  • Headache (secondary to cerebral vasodilation)
  • Facial flushing and warmth
  • Nasal congestion or rhinitis
  • Dyspepsia and gastrointestinal discomfort
  • Dizziness or lightheadedness

Uncommon but documented adverse events include back pain, myalgia, altered visual perception (such as a temporary blue-green color tinge or photophobia), and epistaxis. Post-marketing surveillance has identified rare instances of sudden decreased vision or permanent vision loss attributed to Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), as well as sudden sensorineural hearing loss, occasionally accompanied by tinnitus.

Important Precautions and Special Populations

Prior to initiating treatment with vardenafil, a comprehensive cardiovascular evaluation should be performed. Sexual exertion carries an inherent risk of cardiac stress; thus, vardenafil therapy is generally not recommended for men with unstable angina, recent myocardial infarction or cerebrovascular accident (within the preceding 6 months), severe heart failure (NYHA Class III or IV), or uncontrolled cardiac arrhythmias.

Vardenafil has been shown to produce modest, concentration-dependent prolongations of the QTc interval. Clinicians should exercise caution when prescribing vardenafil to patients with a documented history of QTc prolongation or those concurrently taking Class IA (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic agents. In special populations, safety and efficacy in pediatric individuals (under 18 years of age) have not been established, and the medication is not indicated for use in females.

Food and Alcohol Considerations

The rate and total extent of vardenafil absorption can be modified by concurrent food intake. When vardenafil is taken alongside a high-fat meal (defined as containing approximately 57% fat content), the mean Tmax may be delayed by approximately 60 minutes, accompanied by a mean reduction in Cmax of roughly 18 to 20%. To achieve predictable onset of action, administration on an empty stomach or with a light, non-fatty meal is generally recommended.

Moderate alcohol ingestion does not appear to alter vardenafil pharmacokinetics significantly. However, because both alcohol and vardenafil exert mild blood-pressure-lowering vasodilatory effects, simultaneous consumption of substantial quantities of alcohol can increase the incidence of orthostatic reactions, including postural hypotension, tachycardia, dizziness, and headache.

Managing Skipped Doses

Valif is intended for use on an as-needed (PRN) schedule prior to planned sexual activity, rather than as a continuous daily regimen. Consequently, routine missed dose management principles do not typically apply.

If a healthcare provider has advised a specific dosing frequency, and a scheduled dose is skipped, the patient should take the missed tablet only when remembered, provided there is sufficient time prior to intended sexual activity. Patients must never double the prescribed dosage or administer more than one dose within a 24-hour window to compensate for an omitted tablet.

Storage Specifications and Expiry

Valif tablets should be stored within their original packaging to protect the contents from environmental exposure. Recommended storage parameters require controlled room temperature maintained between 68°F and 77°F (20°C to 25°C). Excursions are temporarily permitted between 59°F and 86°F (15°C and 30°C) in alignment with United States Pharmacopeia (USP) guidelines.

Keep the medication away from excessive moisture, direct sunlight, and high heat environments, such as bathroom cabinets. Store securely out of the reach and sight of children and domestic pets. Do not consume tablets beyond the expiration date clearly printed on the blister foil or external carton. Unused or expired pharmaceuticals must be disposed of via community drug take-back programs or in strict compliance with federal and state environmental standards.

Red Flag Symptoms and Emergency Protocols

Certain clinical signs mandate immediate cessation of the medication and urgent emergency medical intervention. Patients experiencing severe cardiovascular symptoms during or following sexual activity–such as acute chest pressure, radiation of pain to the jaw or arm, severe dyspnea, or syncope–must seek emergency medical care immediately.

Priapism, defined as an erection persisting longer than 4 hours, represents a critical urological emergency. Immediate medical evaluation is required to prevent ischemic damage to cavernous tissue, which can lead to permanent erectile dysfunction. Furthermore, any sudden loss of vision in one or both eyes or a sudden drop or loss of hearing requires immediate emergency clinical evaluation.

Emergency Indicator Clinical Significance Required Action
Chest Pain / Pressure Potential acute coronary syndrome or myocardial ischemia Stop activity; seek immediate emergency services (911)
Erection Duration > 4 Hours Ischemic priapism risk with tissue necrosis potential Seek emergency room intervention immediately
Sudden Visual Loss Possible Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Discontinue drug; contact ophthalmologist/ER immediately
Sudden Hearing Loss Otological toxicity or vascular events Discontinue drug; seek prompt medical evaluation
Severe Hypersensitivity Anaphylaxis, angioedema, facial swelling, or severe rash Obtain emergency emergency medical support immediately

Frequently Asked Questions

What is the typical time frame for vardenafil to become active after oral ingestion?

Vardenafil is generally absorbed rapidly, with therapeutic onset typically occurring between 30 and 60 minutes following oral ingestion. Because sexual stimulation is required to initiate local nitric oxide release, the drug will not produce an erection without arousal. Consuming the medication with high-fat meals may delay the onset of clinical effect.

How does vardenafil interact with medications prescribed for blood pressure?

Vardenafil possesses systemic vasodilatory properties that can add to the blood-pressure-lowering effects of antihypertensive agents. Particular caution is required when co-administering with alpha-blockers, as combination therapy can induce orthostatic hypotension. Patients should be hemodynamically stable on their blood pressure regimen before starting vardenafil, and dosages should be managed under clinical supervision.

Is it permissible to split or crush Valif tablets?

Valif tablets are designed to be swallowed whole with water to ensure appropriate absorption and consistent dosing accuracy. Splitting, crushing, or chewing tablets is not recommended unless explicitly specified by the product label or directed by a prescribing clinician.

What should be done if vardenafil does not produce the expected therapeutic response?

Therapeutic response can vary based on timing, psychological factors, underlying vascular disease, or improper administration (e.g., taking the drug after a heavy meal). If an adequate response is not achieved, patients should consult their prescribing physician to re-evaluate the treatment plan. Patients should never independently increase the dose or frequency of administration.

Are there specific restrictions regarding grapefruit juice while taking vardenafil?

Yes. Grapefruit juice acts as an inhibitor of the intestinal CYP3A4 enzyme system. Consuming grapefruit or grapefruit juice alongside vardenafil can increase systemic drug levels and peak plasma concentrations, potentially heightening the risk and severity of adverse effects. Avoiding grapefruit products during treatment is generally advised.

In accordance with FDA requirements.

Information on this page is for reference and does not replace an assessment by a licensed healthcare professional.

Additional information
Dosage

20mg

Package

10 pills

,

20 pills

,

30 pills

,

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία